Study of new treatments for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests new drugs for people with advanced squamous non-small cell lung cancer that has gotten worse after standard treatments like immunotherapy and chemotherapy. The goal is to find better options for those who need them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV squamous non-small cell lung cancer that has spread.
- Your cancer must have worsened after receiving immunotherapy (PD-1/PD-L1 treatment) and platinum-based chemotherapy.
- If you have HIV, it must be well controlled with medication.
- If you have hepatitis B or C, the virus must be undetectable with treatment.
- You cannot have certain heart, lung, eye, or autoimmune conditions, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Hear when a new Lung Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.